Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539925 | 1.00 | KLK5 (0.46) | KLK5ACEMAPTTDP1KMT2A | |
| SCHEMBL20646383 | 1.00 | KLK5 (0.46) | KLK5ACEMAPTTDP1KMT2A | |
| SCHEMBL31478692 | 1.00 | KLK5 (0.46) | KLK5ACEMAPTTDP1KMT2A | |
| SCHEMBL30722033 | 0.91 | CTSS (0.47) | ACEMAPTTDP1CTSSCTSL | |
| SCHEMBL18495625 | 0.91 | CTSS (0.47) | ACEMAPTTDP1CTSSCTSL | |
| SCHEMBL30597646 | 0.91 | CTSS (0.47) | ACEMAPTTDP1CTSSCTSL | |
| SCHEMBL30597634 | 0.91 | CTSS (0.47) | ACEMAPTTDP1CTSSCTSL | |
| SCHEMBL27332954 | 0.91 | CTSS (0.47) | ACEMAPTTDP1CTSSCTSL | |
| SCHEMBL18495627 | 0.90 | ATM (0.48) | KMT2APOLB | |
| SCHEMBL31246036 | 0.89 | KMT2A (0.43) | KLK5ACEMAPTTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025026216-A9 | PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY-DRUG CONJUGATE OF GLUCOCORTICOID | 江苏恒瑞医药股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2024140917-A1 | ANTI-CD40 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海盛迪医药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024140903-A1 | COMPOSITION OF CD40-BINDING MOLECULE AND PHARMACEUTICAL USE THEREOF | 苏州盛迪亚生物医药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| CN-113929738-B | Antibody-drug conjugates | 第一三共株式会社 | 2024-05-17 | — | — | CN | disclosed |
| CN-110464847-B | anti-HER 2 antibody-drug conjugates | 第一三共株式会社 | 2024-02-09 | — | — | CN | disclosed |
| US-11795236-B2 | Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| WO-2023143351-A1 | DRUG CONJUGATE OF GLUCOCORTICOID | 上海盛迪医药有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-109081871-B | Antibody-drug conjugates | 第一三共株式会社 | 2023-07-14 | — | — | CN | disclosed |
| US-11633493-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-25 | — | — | US | disclosed |
| CN-113929738-A | Antibody-drug conjugates | 第一三共株式会社 | 2022-01-14 | — | — | CN | disclosed |
| US-10973924-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| US-20200385486-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| US-20200282073-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20190077880-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-03-14 | — | — | US | disclosed |
| US-10195288-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-05 | — | — | US | disclosed |
| US-9808537-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-07 | — | — | US | disclosed |
| US-20160333112-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633493-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | KLK5 3970/4885ACE 2626/4885MAPT 949/4885 |
| US-20200385486-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | KLK5 2678/4885ACE 1821/4885MAPT 1489/4885 |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ADCY3, ADCY8, ADCY7 | KLK5 1030/4885ACE 4322/4885MAPT 327/4885 |
| US-20200282073-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | KLK5 3970/4885ACE 2626/4885MAPT 949/4885 |
| US-20160333112-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | KLK5 3694/4885ACE 2096/4885MAPT 1142/4885 |
| US-10973924-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | KLK5 4108/4885ACE 2620/4885MAPT 874/4885 |
| US-10195288-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | KLK5 4108/4885ACE 2620/4885MAPT 874/4885 |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | KLK5 4108/4885ACE 2620/4885MAPT 874/4885 |
| US-11795236-B2 | Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate | ERBB2, EGFR, ERBB3 | KLK5 2687/4885ACE 1856/4885MAPT 1549/4885 |
| US-20190077880-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | KLK5 3628/4885ACE 2091/4885MAPT 1150/4885 |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | KLK5 4108/4885ACE 2620/4885MAPT 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.